



## ASX ANNOUNCEMENT

### CELLMID APPOINTS DR FINTAN WALTON AS NON-EXECUTIVE DIRECTOR

**SYDNEY, Tuesday, 21 July, Cellmid Limited (ASX: CDY)** is pleased to advise that it has appointed Dr Fintan Walton as non-executive director, effective immediately. Dr Walton has over 33 years experience in the global pharmaceutical and biotechnology sector.

He is Founder and CEO of PharmaVentures Ltd, a UK based corporate advisory firm with more than 30 professional advisers, assisting pharmaceutical and biotechnology companies worldwide in all aspects of corporate transactions, business brokering, mergers and acquisitions and licensing deals. Since he founded PharmaVentures in 1992, he and his team have advised blue chip clients in North America, Europe and Asia, delivering more than 700 assignments for 180 companies in 38 countries.

Dr Walton has worked with clients including most of the major and mid-sized pharmaceutical and biotechnology companies. His experience extends to industries such as pharmaceuticals, diversified chemicals, diagnostics, medical devices, generic and over-the-counter medicines as well as government agencies. He has transactional experience representing corporates as well as major banks, investment and merchant banks, private equity and venture capital groups.

Educated at Trinity College (Dublin, Ireland), where he obtained his PhD in genetics, Dr Walton has subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992) prior to founding PharmaVentures.

"I am very pleased to join Cellmid at this exciting stage of its development, when the Company is poised to deliver value out of its intellectual property portfolio around midkine, as well as its FGF5 inhibitor technology" said Dr Walton.

"We are delighted to welcome Fintan onto the Board as non-executive director" said Chairman of Cellmid Dr David King. "Fintan's unparalleled transactional experience and understanding of the global deal making environment will be invaluable in both our midkine and consumer health businesses" he added.

End

Contact:

Dr David King, Chairman  
T +612 9221 6830



### **Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company with lead drug candidates in oncology and nephropathy. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications and kidney diseases. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see [www.cellmid.com.au](http://www.cellmid.com.au).

### **Consumer Health - Advangen Limited**

In 2013 Cellmid acquired Advangen Inc. (Japan), the owner of a range of FGF5 hair growth technologies and products. Since then, Cellmid's FGF5 inhibitor assets have been consolidated in its wholly owned subsidiary, Advangen Limited. Cellmid, under Advangen Limited, has continued innovation and product development in addition to actively building distribution in Australia, China, Japan and other major markets. Since the acquisition of Advangen Inc., Advangen Limited filed a number of new patent applications covering several hair growth agents including midkine, pleiotrophin and a group of novel FGF5 inhibitors.

### **Investment in life sciences companies**

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.